Kevin A. Lobo

Biography

We appointed Kevin A. Lobo as Chairman of the Board on July 22, 2014, in addition to his responsibilities as Chief Executive Officer of Stryker Corporation, which he assumed on October 1, 2012.  Mr. Lobo joined Stryker in 2011, and had previously been Group President of Orthopaedics. Mr. Lobo serves on the Board of Directors for Parker Hannifin Corporation, the global leader in motion and control technologies.  He is also a board member of the Advanced Medical Technology Association (AdvaMed), the Business Leaders for Michigan and United Way for Kalamazoo/Battle Creek regions, and is a member of the Business Roundtable.  Mr. Lobo has a broad business career that includes executive positions in general management and finance.  After holding finance positions with KPMG, Unilever and Kraft Canada he spent eight years with Rhone-Poulenc, including roles based in Europe as Worldwide Corporate Controller of the chemical spin-out, Rhodia, and General Manager of Specialty Phosphates EMEA.  He then spent eight years at Johnson & Johnson, including CFO of McNeil Consumer Healthcare and Ortho Women’s Health & Urology, President of J&J Medical Products Canada and President of Ethicon Endo Surgery. We appointed Kevin A. Lobo as Chairman of the Board on July 22, 2014, in addition to his responsibilities as Chief Executive Officer of Stryker Corporation, which he assumed on October 1, 2012.  Mr. Lobo joined Stryker in 2011, and had previously been Group President of Orthopaedics. Mr. Lobo serves on the Board of Directors for Parker Hannifin Corporation, the global leader in motion and control technologies.  He is also a board member of the Advanced Medical Technology Association (AdvaMed), the Business Leaders for Michigan and United Way for Kalamazoo/Battle Creek regions, and is a member of the Business Roundtable.  Mr. Lobo has a broad business career that includes executive positions in general management and finance.  After holding finance positions with KPMG, Unilever and Kraft Canada he spent eight years with Rhone-Poulenc, including roles based in Europe as Worldwide Corporate Controller of the chemical spin-out, Rhodia, and General Manager of Specialty Phosphates EMEA.  He then spent eight years at Johnson & Johnson, including CFO of McNeil Consumer Healthcare and Ortho Women’s Health & Urology, President of J&J Medical Products Canada and President of Ethicon Endo Surgery.

Research Interest

phrma